VANCOUVER, BC / ACCESSWIRE / May 29, 2015 / Naturally Splendid Enterprises Ltd. (the “Company”) (FRANKFURT:50N) (TSX VENTURE:NSP) (OTC:NSPDF) is excited to announce the official launch of their new, plant-based bulk division, BCI (also known as BC Ingredients). Many of the ingredients will be manufactured at POS Bio-Sciences in their BPC Facility located in Saskatoon, Saskatchewan. The website for BCI can be found at www.bcingredients.com and will be live on Monday June 1st, 2015

BCI’s specially selected plant-based extracts, oils, and powders provide nutrient dense, rich flavor profiles cultivated from around the world. Combined with NSE’s R&D strategic alliance with POS Bio-sciences, BCI can further refine and formulate these extracts to be integrated into foods, beverages, cosmeceuticals, livestock feed, pet foods and more.

The strategic launch of BCI by NSE is to capture a new and emerging bioactive ingredient market. Examples of bioactive ingredients are proteins, plant extracts, minerals, vitamins, fibers, and applications can include, but are not limited to, functional foods, beverages, animal nutrition, personal care, and livestock feed. Bioactive ingredients address the growing awareness of consumers wanting to eat functional foods and beverages or personal care items rather than suffer from pill fatigue. According to Markets and Markets, “these ingredients are essential for various health purposes and help to prevent chronic diseases that typically occur due to lack of nutrients in the body. According to the report, the bioactive ingredients market is estimated to grow from $23.8 billion in 2013 to $33.6 billion in 2018 at a CAGR of 7.2% from 2013 to 2018.” This demand can be met and the expectation can be exceeded with BCI’s line-up of high-quality, plant-based, bioactive ingredients.

HempOmega(R), BCI’s flagship ingredient, is a homogenous, water-soluble powder that is extracted from 100% non-GMO Canadian hemp seeds using NSE’s proprietary microencapsulation technology. HempOmega(R) is a value-added ingredient capable of meeting and exceeding the demand for sustainable plant-based omegas, and boasts versatility, an incredible nutritional profile, and both planet and bio-sustainability. In addition, high-quality hemp-based proteins will also be available through BCI. The global protein market is expected to reach $24.5 billion in 2015, with the greatest annual growth occurring in the plant-protein ingredient sector. There is an increasing number of plant-based protein sources being introduced into the marketplace that offer quality nutrition, taste and sustainability unlike their meat-based counterparts.

About Naturally Splendid

Naturally Splendid is a multifaceted, biotechnology company that is developing, commercializing, producing, selling and licensing an entirely new generation of hemp-derived, high quality, nutrient-dense Omega foods, nutritional foods, nutritional food enhancers, and related products. NSP is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of Cannabis Sativa, industrial hemp, and non-psychoactive cannabinoid compounds in a broad spectrum of applications. The Company is currently innovating in four related industries: nutritional biotechnologies, cannabinoid pharmaceuticals and nutraceuticals, retail superfood and supplement consumer products (under NATERA(TM), a hemp foods line, and Pawsitive FX(TM), a pet care line (TM), as well as a bulk ingredient division operating under the name BC Ingredients (BCI).

About POS Bio-Sciences

POS Bio-Sciences offers expertise and service in bioprocessing applied research from bench-top to commercialization scale. POS’ focus is process development, analytical services, and custom processing as well as specializing in extraction, fractionation, modification and purification of biobased materials.

All POS Bio-Sciences processes are GMP-compliant and fully supported by quality assurance, commitment to regulatory compliance, and certification to international standards. POS’ also offers a suite of support services to assist clients and ensure that project outcomes meet their needs and expectations.

POS Bio-Sciences is a registered business name of POS Management Corp

About Full Spectrum Labs Limited

Full Spectrum Laboratories, LTD. incorporated in Ireland, is a bioresearch and product development company with operating subsidiaries in Canada and the United States. The company has principally focused on the plant cannabis sativa and has developed numerous technologies and made several discoveries resulting in two granted patents and over 11 patent applications, in just under 5 years. FSL currently concentrates on formulation and extraction technologies; analytical cannabis testing in Canada; advance cannabis plant breeding specializing in CBD expression; and cannabinoid bio-synthesis

For more information e-mail info@naturallysplendid.com or call 604-673-9573

On Behalf of the Board of Directors

J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)

2435 Beta Avenue
Burnaby, BC, V5C 5N1

Phone: (604) 570-0902
Fax: (604) 570-0934
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control. There is no guarantee that the Company’s plans will be found to be commercially viable, POS will be successful in developing new plant based omega products; the costs to develop these products will not be higher than anticipated; the Company’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd. 

ReleaseID: 429388

VANCOUVER, BC / ACCESSWIRE / May 29, 2015 / Mezzi Holdings Inc. (“Mezzi” or the “Company”) (TSX-V: MZI, FRA: 0MZ) is pleased to announce the addition of Dr. John Veltheer to the Board of Directors, replacing independent director, Robert Withers.

John Veltheer is a veteran business consultant and strategic investor who serves as an officer or director of a number of private and public companies including: Tinkerine Studios Ltd., a 3-D printer manufacturing company and Atlas Cloud Enterprises Inc., a co-location and cloud computing company. Dr. Veltheer obtained his Bachelor of Science in Chemistry (Honours) from Queen’s University in 1988 and his Ph.D. (Inorganic Chemistry) from the University of British Columbia in 1993. 

The board wishes to thank Mr. Withers for his contribution to the Company during its launch.

“I am very pleased to welcome John to the Board of Directors. He’ll make a great addition to the team and brings a strong track record of business growth combined with additional capital markets experience to the Company,” Keir Reynolds, CEO, commented.

Mr. Raif Adelberg has resigned as President and Chief Designer/Creative Art Director, effective May 28, 2015. Over the past year, Mr. Adelberg has applied his talent and expertise in the fashion industry to assist in the development of MEZZI’s line of handcrafted leather accessories. The Company thanks Mr. Adelberg for his service and wishes him all the best in the future as he steps down from the Board of Directors and resigns to pursue other ventures.

The Company has previously added additional talent in the areas of product design, operations and retail with the appointments of New York-based designer, Kevin Costello, as its head accessories designer and former Indochino executive, Jennifer Clarke, as its Chief Operating Officer.

Mr. Costello is a 20+ year industry expert in the leather goods and accessories markets, having operated as both head designer and consultant to a wide array of internationally recognized brands including Vince Camuto, Shinola, Calvin Klein, Cole Haan, Jones Apparel Group, Tommy Hilfiger, Links of London, Liz Claiborne, Ralph Lauren, Mackage and now MEZZI.

Ms. Clarke began her successful career in 2004 with Abercrombie and Fitch as a Senior Recruiter where she was responsible for managing a team of district recruiters throughout North America. Subsequently, she worked in management roles for the likes of Aritzia, Club Monaco and most recently Indochino, located in Vancouver, British Columbia, where she has spent the last two years as the Director of Retail.

Subject to the approval of the TSX Venture Exchange, the Company has agreed to issue 150,000 common shares in settlement of certain outstanding obligations. Upon issuance, the shares will be subject to a four-month hold period.

About MEZZI

MEZZI is disrupting the status quo in the luxury accessories market as it recently unveiled a beautiful new product line featuring cutting edge technology, making MEZZI the true smart luxury brand. Each piece, including handbags, duffel bags and essential leather goods, allows wireless connectivity between your MEZZI bag and smartphone, providing a completely new user experience. With fine leather sourced directly from Italy, all pieces in the MEZZI Smart Luxury collection are manufactured to precision quality.

For further information please contact:

Mr. Keir Reynolds
CEO
Tel: (778) 998-9242
Email: keir@mezzi.com

ON BEHALF OF THE BOARD

Keir Reynolds
Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially because of factors discussed in the management discussion and analysis section of our interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulations. We do not assume any obligation to update any forward-looking statements, except as required by applicable laws.

SOURCE: Mezzi Holdings Inc. 

ReleaseID: 429386

VANCOUVER, BC / ACCESSWIRE / May 29, 2015 / Rock Tech Lithium Inc. (TSX-V: RCK) (the “Company” or “Rock Tech”) is pleased to announce that all matters set forth in the management proxy and information circular dated April 24, 2015 (the “Circular”) were approved by the shareholders of Rock Tech at the Company’s 2015 Annual General and Special Meeting (the “Meeting”) in Vancouver on May 29, 2015.

All directors, as set forth in the Circular, were elected with each director receiving 99.86% of the votes cast for the election of directors. Mr. Dirk Harbecke, Dr. Christian Schlag and Mr. Martin Stephan were re-elected to the board. Dale Matheson Carr-Hilton Labonte LLP was re-appointed as the auditor, receiving 99.88% of the votes cast for the appointment of auditors. The Company’s stock option plan was approved, receiving 99.77% of the votes cast for the approval of the stock option plan. Similarly, all acts and deeds and other business were approved, each receiving 99.86% of the votes cast for the respective motions.

Over six million shares were voted at the Meeting, representing 40.89% of the total shares issued and outstanding.

On behalf of the Board of Directors,

“Martin Stephan”

Martin Stephan
Director, Chief Executive Officer

For more information, please contact:

Brad Barnett
Chief Financial Officer
Rock Tech Lithium Inc.
1021 West Hastings Street, Suite 900
Vancouver, B.C., V6E 0C3
Telephone: (604) 558.5123
Facsimile: (604) 670.0033
Email: bbarnett@rocktechlithium.com

Disclaimer and Cautionary Statement Regarding Forward-Looking Information

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction.

All statements, trend analysis and other information contained in this press release relative to markets about anticipated future events or results constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change. Investors should not place undue reliance on forward-looking statements.

SOURCE: Rock Tech Lithium Inc. 

ReleaseID: 429387

TOKYO, JAPAN / ACCESSWIRE / May 29, 2015 / Aqua Power Systems Inc. (OTCQB: APSI) (the “Company”) is pleased to announce that it has signed a Licensing and Option Agreement with Tadashi Ishikawa, our chief executive, director and majority shareholder, and Aqua Power System Japan Kabushiki Kaisha (“Aqua Power Japan”), a company specializing in the development, manufacturing, and commercialization of magnesium air fuel cell technologies for generating safe, green, reliable and inexpensive off-grid electricity, which is also operated by Mr. Ishikawa.

The Licensing and Option Agreement, subject to its terms and conditions, provides the Company with the exclusive worldwide rights to manufacture, market, and distribute all RMAF fuel cell technologies and products developed by Aqua Power Japan. In addition, also subject to certain terms and conditions, the Licensing and Option Agreement provides the Company with an option to purchase Aqua Power Japan. The renewable Licensing and Option Agreement is for a term of 10 years. 

“We are very pleased to have quickly completed an exclusive worldwide licensing agreement for Aqua Power Japan’s patented water activated RMAF magnesium air fuel cell technologies,” commented Tadashi Ishikawa, President of Aqua Power Systems Inc. Furthermore, “These products and technologies have already been proven under the demanding conditions in the Japanese market since 2009. Now, as a result of a rapid increase in interest in clean, portable, and scalable battery technologies for home, commercial, and automotive applications, the timing of this licensing agreement has positioned the Company to expand distribution and build public awareness of RMAF fuel cell technologies and products on a global scale.”

ABOUT AQUA POWER JAPAN 

Founded in Japan in 2004, Aqua Power Japan develops, manufactures and has successfully commercialized magnesium air fuel cells for generating safe, green, reliable and inexpensive off-grid electricity. Aqua Power Japan’s patented (and patent pending) Realistic Magnesium Air Fuel System (“RMAF”) technology causes electricity to be generated from the chemical reaction of the combination of magnesium, oxygen (air) and a saltwater electrolyte. RMAF powered applications can be refueled using its proprietary lightweight magnesium rods, which fuel the chemical reaction.

RMAF fuel cells have a long shelf, are lightweight, transportable, environmentally friendly, safe and scalable for greater power generation. Aqua Power Japan has aggressively patented (16 patents and patents-pending to date) and protects its intellectual property in Japan and internationally.

Aqua Power Japan’s fuel cell technology can be applied to many applications requiring remote power, including emergency preparedness and disaster relief, outdoor recreation, industry (mining, oil and gas, forestry), military, marine (saltwater environments), and automotive opportunities (main drive, electrical subsystems, and backup systems).

Aqua Power Japan has been generating revenue since its initial products were launched in 2009 in Japan. These products included a water-activated AA battery (more than 8 million sold to date), mini-LED flashlights, and portable radios. Aqua Power Japan products gained national attention in Japan following the earthquake and tsunami that devastated many parts of the country in 2011.

For additional information regarding Aqua Power, please visit www.aquapowersystems.com.

On behalf of the Board Tadashi Ishikawa, President

For further information please contact: info@aquapowersystems.com. 

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with intellectual property protection, marketing and sale, manufacturing and distribution and difficulties associated with obtaining financing on acceptable terms. We are not in control of energy trends and prices and these could vary to make our business development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

SOURCE: Aqua Power Systems Inc. 

ReleaseID: 429385

WEST PALM BEACH, FL / ACCESSWIRE / May 29, 2015 / Solitron Devices, Inc. (OTCQB: SODI) (the “Company”) today announced that its Board of Directors declared a cash dividend of $0.25 per share of common stock. The dividend will be paid on or about July 22, 2015 to stockholders of record as of the close of business on June 29, 2015. 

The Company also announced that its Board of Directors has authorized a repurchase program of up to $500,000 of the Company’s common stock through February 29, 2016. Purchases may be made through the open market or privately negotiated transactions as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements and other conditions.

“We are continuing to return capital to our stockholders by paying our second cash dividend since emerging from bankruptcy in 1993. This cash dividend reflects an increase of $0.20 per share of common stock over the cash dividend paid last year of $0.05 per share. We believe the authorization of a stock repurchase program will also create further value for our stockholders. We are committed to enhancing and returning stockholder value. We will continue to regularly review our capital management strategy and evaluate opportunities to return capital to our stockholders,” said Shevach Saraf, Chairman, Chief Executive Officer, President, Chief Financial Officer and Treasurer of the Company.

About Solitron Devices, Inc.

Solitron Devices, Inc., a Delaware corporation, designs, develops, manufactures and markets solid-state semiconductor components and related devices primarily for the military and aerospace markets. The Company manufactures a large variety of bipolar and metal oxide semiconductor (“MOS”) power transistors, power and control hybrids, junction and power MOS field effect transistors (“Power MOSFETS”), field effect transistors and other related products. Most of the Company’s products are custom made pursuant to contracts with customers whose end products are sold to the United States government. Other products, such as Joint Army/Navy transistors, diodes and Standard Military Drawings voltage regulators, are sold as standard or catalog items. The Company was incorporated under the laws of the State of New York in March 1959, and reincorporated under the laws of the State of Delaware in August 1987. 

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and the future performance of Solitron Devices, Inc. that involve risks and uncertainties that could materially affect actual results, including statements regarding the timing and payment of the cash dividend and our ability to consummate repurchases under the stock repurchase program. Factors that could cause actual results to vary from current expectations and forward-looking statements contained in this press release include, but are not limited to: (1) changes in our stock price, corporate or other market conditions; (2) the loss of, or reduction of business from, substantial clients; (3) our dependence on government contracts, which are subject to termination, price renegotiations and regulatory compliance; (4) changes in government policy or economic conditions; (5) increased competition; (6) the uncertainty of current economic conditions, domestically and globally; (7) environmental regulations; and (8) other factors contained in the Company’s Securities and Exchange Commission filings, including its Form 10-K, 10-Q and 8-K reports.

CONTACT:

SHEVACH SARAF
(561) 848-4311

SOURCE: Solitron Devices, Inc.

ReleaseID: 429380

CALGARY, AB / ACCESSWIRE / May 29, 2015 / Imaging Dynamics Company, Ltd. (“IDC” or the “Company”) (TSX Venture: IDL-X) is pleased to announce today the financial results for the 2015 first quarter ended March 31, 2015.

2015 First Quarter Highlights

Gross revenues for the first quarter of 2015 were $0.485 million compared to $0.398 million for the same quarter last year representing an increase of 21.8% in revenues. The increase in revenues during the period is mainly due to sales in the Asia-Pacific, USA and Latin America regions which have been the focus of IDC’s management team over the past year.

Sales and marketing, general and administrative, production and manufacturing, and research and development expenses were lower by 10.6 percent to $0.476 million from $0.533 million during the first quarter compared to the same quarter last year, due to IDC’s continued cost reduction initiatives.

Net loss for the first quarter ended March 31, 2015 was $0.288 million compared to a net loss of $0.398 million for the same quarter last year, a significant improvement of 23.6% in performance over the prior period results.

Dr. Sidong Huang, President and CEO of the Company stated: “IDC continues to progress towards generating revenues and making improvements in its operations in 2015. The efforts demonstrated by IDC’s employees, management team and Board of Directors have shown marked improvements in operating results in the first quarter.” The Company’s focus on sales and marketing efforts have resulted in increased sales from IDC’s existing customer base and distribution partners, and in the development of new business relationships with new potential major customers.

About Imaging Dynamics Company (IDC):

IDC is a global medical imaging technology provider and innovative force in the high growth field of digital radiography (DR) technology.

The Company has over 4,000 installations in 50 countries of its proprietary, award winning direct capture DR technology, which replaces conventional film-based diagnostic imaging and provides a cost-effective solution for medical facilities of all sizes to provide high quality diagnostic X-ray images and improve the level of healthcare for their patients.

Throughout its history, IDC has been recognized by multiple industry organizations and research analysts such as: Frost & Sullivan and Deloitte Technology; for its dedication to innovation, global market growth, and customer focused value proposition.

The Company has its corporate office in Calgary, Alberta, Canada, and a representative office in Beijing, China.

Visit the IDC web site: www.imagingdynamics.com

For more information, please contact:

Sidong Huang
President and Chief Executive Officer
Imaging Dynamics Company Ltd.
1.403.251.9939 Office
1.866.975.6737 Toll Free
sidong@imagingdynamics.com

Statements in this release which describe IDC’s intentions, expectations or predictions, or which relate to matters that are not historical
facts are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties which may
cause the actual results, performances or achievements of IDC to be materially different from any future results, performances or
achievements expressed in or implied by such forward-looking statements. IDC may update or revise any forward-looking statements,
whether as a result of new information, future events or changing market and business conditions. Known and unknown risks and
uncertainties include: IDC’s ability to manufacture its products with a sufficient level of quality and in volumes which satisfy market demand;
the ability of IDC to establish direct and indirect sales channels; the ability of IDC to establish industry partnerships; IDC’s ability to attract
and retain key personnel; the strength and breadth of IDC’s patents; and other factors relating to general economic conditions, specific industry conditions and IDC’s particular situation.

SOURCE: Imaging Dynamics Company Ltd.

ReleaseID: 429374

TORONTO, ON / ACCESSWIRE / May 29, 2015 / Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink(R)), a medical laser company dedicated to commercializing technology to heal pain and destroy cancer, released its first quarter 2015 financial results today, demonstrating an increase of 2% in revenue year over year.

In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT“) and Photo Dynamic Therapy (“PDT“) anti-cancer divisions.

In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000, with patented Cell Sensing(TM) technology, is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue faster and more effectively than any other laser system on the market.

In the PDT division, Theralase has significantly advanced its anti-cancer technology, focused initially on the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC“), and is gearing up for enrollment of patients in a Health Canada Phase Ib clinical study.

To meet this goal, Theralase has:

– Assembled an illustrious Medical and Scientific Advisory Board (“MSAB“) in 4Q2014
– Presented its anti-cancer technology to Health Canada during a Clinical Trial Application (“CTA“) meeting that occurred in 1Q2015
– Commenced the manufacturing process of its lead Photo Dynamic Compound (“PDC“) TLD-1433 to Good Manufacturing Practice (“GMP“) certification standards for completion of a Drug Master File (“DMF“) slated for 3Q2015
– Commenced toxicology analysis of its lead drug, TLD-1433
– Commenced compiling the clinical protocol and investigator’s brochure

Completion of these key objectives will result in submission of a CTA package to Health Canada in 3Q2015 and pending approval, enrolling patients that meet the inclusion / exclusion criteria into a Phase Ib clinical study for NMIBC in 4Q2015.

Total revenue for the three-month period ended March 31, 2015 increased 2% to $368,304 from $361,179 year over year.

The net loss for the three-month period ended March 31, 2015 was $933,643 (including $165,531 of net non-cash expenses) compared to a net loss of $344,074 in 2014 (including $15,897 of net non-cash expenses).

The net loss is a reflection of the ongoing commitment of Theralase to invest in the next generation of therapeutic laser technology and state-of-the-art anti-cancer treatment technology, partially funded from existing therapeutic laser sales. 

Selling and marketing expenses increased 51% to $184,488 from $122,278 for the same period in 2014, primarily due to increased spending in associated marketing costs.

Administrative expenses increased 89% to $456,123 from $240,373 for the same period in 2014. The increase in administrative expenditures was due to increased spending on investor relations activities and medical advisory fees.

Research and development costs increased 276% to $545,645 from $197,792 for the same period in 2014. The increase was due to increased expenditures and investment into the commercialization of the TLC-2000 therapeutic laser technology and research and development of the TLC-3000 anti-cancer technology.

Roger Dumoulin-White, President and CEO of Theralase stated, “2015 will be a very strategic year for Theralase, as it launches the next generation TLC-2000 with Cell Sensing(TM) technology both in Canada and the United States and commences enrolling patients in a Health Canada Phase Ib clinical study for NMIBC.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase(R)“) (TSXV: TLT) (TLTFF: OTC Pink(R)) in its Therapeutic Laser Technology (“TLT“) Division designs, manufactures and markets patented super-pulsed laser technology indicated for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT“) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs“), which are able to localize to the cancer cells and then, when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information: 

Roger Dumoulin-White
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

Kristina Hachey
Chief Financial Officer, Theralase Technologies
1.866.THE.LASE (843-5273) ext. 224
416-699-LASE (5273) ext. 224
khachey@theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 429376